Gilead exercised an option to license Kymera Therapeutics’ preclinical molecular glue degrader targeting CDK2, injecting another candidate into a rapidly expanding oncology pipeline. Under the deal, Gilead paid $45 million for the option, with potential development, regulatory, and commercial milestones that could reach $665 million. Gilead will hold global rights to the oral degrader candidate KT-200. Kymera’s approach uses a targeted protein degradation mechanism designed to eliminate CDK2 rather than inhibit it, aiming for differentiation from clinical-phase CDK2 inhibitors. Kymera reported low-nanomolar CDK2 degradation in preclinical work, and Gilead plans to run IND-enabling studies with a goal of entering humans next year. The move adds to the wave of big-pharma buy-ins into degrader modalities, reflecting continued investor appetite for molecular glue and related targeted degradation formats where selectivity and therapeutic windows are key product-defining factors.